Factor XIII Deficiency Does Not Prevent FeCl-induced Carotid Artery Thrombus Formation in Mice

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2020 Jan 29

PMID 31989092

Citations 5

Authors

Zhaoming Tang

Sravya Kattula

Lori A Holle

Brian C Cooley

Feng-Chang Lin

Alisa S Wolberg

Affiliations

Soon will be listed here.

Abstract

Background: The compositions of venous (red blood cell-rich) and arterial (platelet-rich) thrombi are mediated by distinct pathophysiologic processes; however, fibrin is a major structural component of both. The transglutaminase factor XIII (FXIII) stabilizes fibrin against mechanical and biochemical disruption and promotes red blood cell retention in contracted venous thrombi. Previous studies have shown factor XIII (FXIII) inhibition decreases whole blood clot mass and therefore, may be a therapeutic target for reducing venous thrombosis. The role of FXIII in arterial thrombogenesis is less studied, and the particular contribution of platelet FXIII remains unresolved.

Objective: To determine whether FXIII reduction prevents experimental arterial thrombogenesis.

Methods: Using wild-type mice and mice with genetically imposed deficiency in FXIII, we measured thrombus formation and stability following ferric chloride-induced arterial thrombosis. We also determined the impact of FXIII on the mass of contracted platelet-rich plasma clots.

Results: Following vessel injury, , , and mice developed occlusive arterial thrombi. FXIII deficiency did not significantly reduce the incidence or prolong the time to occlusion. FXIII deficiency also did not alter the timing of reflow events or decrease platelet-rich clot mass.

Conclusions: FXIII does not significantly alter the underlying pathophysiology of experimental arterial thrombus formation.

Citing Articles

Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.

Wolberg A, Sang Y Arterioscler Thromb Vasc Biol. 2022; 42(8):931-941.

PMID: 35652333 PMC: 9339521. DOI: 10.1161/ATVBAHA.122.317164.

Role of Neutrophils and NETs in Animal Models of Thrombosis.

Carminita E, Crescence L, Panicot-Dubois L, Dubois C Int J Mol Sci. 2022; 23(3).

PMID: 35163333 PMC: 8836215. DOI: 10.3390/ijms23031411.

Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.

Kattula S, Sang Y, de Ridder G, Silver A, Bouck E, Cooley B J Thromb Haemost. 2021; 19(12):2997-3007.

PMID: 34431201 PMC: 8605765. DOI: 10.1111/jth.15510.

The factor XIII-A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations.

Kattula S, Bagoly Z, Toth N, Muszbek L, Wolberg A J Thromb Haemost. 2020; 18(4):885-894.

PMID: 31989767 PMC: 8059250. DOI: 10.1111/jth.14744.

Factor XIII deficiency does not prevent FeCl-induced carotid artery thrombus formation in mice.

Tang Z, Kattula S, Holle L, Cooley B, Lin F, Wolberg A Res Pract Thromb Haemost. 2020; 4(1):111-116.

PMID: 31989092 PMC: 6971319. DOI: 10.1002/rth2.12278.

References

Gewirtz J, Thornton M, Rauova L, Poncz M . Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. J Thromb Haemost. 2008; 6(7):1160-6. DOI: 10.1111/j.1538-7836.2008.02992.x. View

Machlus K, Lin F, Wolberg A . Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice. Blood. 2011; 118(14):3960-8. PMC: 3193271. DOI: 10.1182/blood-2011-06-362814. View

Pieters M, Wolberg A . Fibrinogen and fibrin: An illustrated review. Res Pract Thromb Haemost. 2019; 3(2):161-172. PMC: 6462751. DOI: 10.1002/rth2.12191. View

Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E . Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011; 91(3):931-72. DOI: 10.1152/physrev.00016.2010. View

Francis C, Marder V . Rapid formation of large molecular weight alpha-polymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII. J Clin Invest. 1987; 80(5):1459-65. PMC: 442404. DOI: 10.1172/JCI113226. View

Shebuski R, Sitko G, Claremon D, Baldwin J, REMY D, Stern A . Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood. 1990; 75(7):1455-9. View

Muszbek L, Katona E . Diagnosis and Management of Congenital and Acquired FXIII Deficiencies. Semin Thromb Hemost. 2016; 42(4):429-39. DOI: 10.1055/s-0036-1572326. View

Jobe S, Leo L, Eastvold J, Dickneite G, Ratliff T, Lentz S . Role of FcRgamma and factor XIIIA in coated platelet formation. Blood. 2005; 106(13):4146-51. PMC: 1895237. DOI: 10.1182/blood-2005-03-1223. View

Popuri R, Vedantham S . The role of thrombolysis in the clinical management of deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2011; 31(3):479-84. PMC: 3424264. DOI: 10.1161/ATVBAHA.110.213413. View

10.

Aleman M, Byrnes J, Wang J, Tran R, Lam W, Di Paola J . Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest. 2014; 124(8):3590-600. PMC: 4109540. DOI: 10.1172/JCI75386. View

11.

Kattula S, Byrnes J, Martin S, Holle L, Cooley B, Flick M . Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice. Blood Adv. 2018; 2(1):25-35. PMC: 5761627. DOI: 10.1182/bloodadvances.2017011890. View

12.

Shortell C, Francis C . Thrombolytic therapy for arterial thrombosis. Curr Opin Hematol. 1999; 6(5):309-13. DOI: 10.1097/00062752-199909000-00007. View

13.

Souri M, Koseki-Kuno S, Takeda N, Degen J, Ichinose A . Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice. Int J Hematol. 2008; 87(1):60-8. DOI: 10.1007/s12185-007-0005-z. View

14.

Owens 3rd A, Lu Y, Whinna H, Gachet C, Fay W, Mackman N . Towards a standardization of the murine ferric chloride-induced carotid arterial thrombosis model. J Thromb Haemost. 2011; 9(9):1862-3. DOI: 10.1111/j.1538-7836.2011.04287.x. View

15.

Valnickova Z, Enghild J . Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem. 1998; 273(42):27220-4. DOI: 10.1074/jbc.273.42.27220. View

16.

Westrick R, Winn M, Eitzman D . Murine models of vascular thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol. 2007; 27(10):2079-93. DOI: 10.1161/ATVBAHA.107.142810. View

17.

Jensen P, Lorand L, Ebbesen P, GLIEMANN J . Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures. Eur J Biochem. 1993; 214(1):141-6. DOI: 10.1111/j.1432-1033.1993.tb17906.x. View

18.

Byrnes J, Duval C, Wang Y, Hansen C, Ahn B, Mooberry M . Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. Blood. 2015; 126(16):1940-8. PMC: 4608241. DOI: 10.1182/blood-2015-06-652263. View

19.

Reed G, Matsueda G, Haber E . Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis. Trans Assoc Am Physicians. 1991; 104:21-8. View

20.

Tang Z, Kattula S, Holle L, Cooley B, Lin F, Wolberg A . Factor XIII deficiency does not prevent FeCl-induced carotid artery thrombus formation in mice. Res Pract Thromb Haemost. 2020; 4(1):111-116. PMC: 6971319. DOI: 10.1002/rth2.12278. View